Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer von Zighelboim, Israel, Wright, Jason D, Gao, Feng, Case, Ashley S, Massad, L. Stewart, Mutch, David G, Powell, Matthew A, Thaker, Premal H, Eisenhauer, Eric L, Cohn, David E, Valea, Fidel A, Alvarez Secord, Angeles, Lippmann, Lynne T, Dehdashti, Farrokh, Rader, Janet S

Volltext

Phase I Study and Preliminary Pharmacology of the Novel Innate Immune Modulator rBBX-01 in Gynecologic Cancers von Rader, Janet S, Aylsworth, Charles F, Juckett, David A, Mutch, David G, Powell, Matthew A, Lippmann, Lynne, Dimitrov, Nikolay V

Volltext

Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer von Zighelboim, Israel, Wright, Jason D., Gao, Feng, Case, Ashley Stephens, Massad, L. Stewart, Mutch, David Gardner, Powell, Matthew A., Thaker, Premal H., Eisenhauer, Eric Lawernce, Cohn, David E., Valea, Fidel A., Secord, Angeles Alvarez, Lippmann, Lynne T., Rader, Janet Sue

Volltext

Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer von Herzog, Thomas J, Powell, Matthew A, Rader, Janet S, Gibb, Randall K, Lippmann, Lynne, Coleman, Robert L, Mutch, David G

Volltext

The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma Collection (TCGA-UCEC) von Erickson, Bradley J., Mutch, David, Lippmann, Lynne, Jarosz, Rose

Volltext bestellen

Serum levels of CA-125 in patients with endometriosis: a preliminary report von Giudice, Linda C., Jacobs, Allan, Pineda, Jorge, Elliott Bell, C., Lippmann, Lynne

Volltext

Letter to the editor von Giudice, Linda C., Jacobs, Allan J., Bell, C.Elliot, Lippmann, Lynne

Volltext

Therapy of ovarian carcinoma: The relationship of dose level and treatment intensity to survival von Jacobs, Allan J., Sommers, Gara M., Homan, Sharon M., Camel, H.Marvin, Axelrod, Janice H., Kao, Ming-Shian, Galakatos, Andrew E., Parham, Judith, Lippmann, Lynne

Volltext